What is Urinary Incontinence?
 

Urinary Incontinence is the involuntary loss of urine that represents a social or hygienic problem to the individual.
 

• Primary Clinical Subtypes:

  • Stress Urinary Incontinence: Involuntary leakage associated with efforts or exertion that increase intra-abdominal pressure (e.g., coughing, sneezing, laughing, lifting, or exercising).

  • Urge Urinary Incontinence/Overactive Bladder: Involuntary leakage accompanied by or immediately preceded by an urgent, overwhelming desire to void.

  • Overflow Incontinence: Continuous or frequent dribbling of urine resulting from an incomplete emptying bladder and urinary retention (underactive detrusor or bladder outlet obstruction).

  • Functional Incontinence: Urine leakage caused by cognitive, physical, or environmental barriers that prevent an individual from reaching the toilet in time (e.g., severe mobility impairment, dementia).

  • Mixed Incontinence: A combination of two or more types, most commonly coexisting stress and urge incontinence.

Primary Causes of Urinary Incontinence
 

• Pelvic Floor Dysfunction & Weakness: Pregnancy, childbirth, vaginal delivery trauma, and aging leading to pelvic floor muscle relaxation and urethral hypermobility.

• Intrinsic Sphincter Deficiency (ISD): Damage or weakening of the urethral sphincter mechanism resulting in poor urethral closure.

• Detrusor Overactivity: Uninhibited contractions of the bladder muscle during the filling phase (neurogenic or idiopathic overactive bladder).

• Bladder Outlet Obstruction: Benign prostatic hyperplasia (BPH), urethral strictures, or severe pelvic organ prolapse compressing the urethra.

• Anatomical Abnormalities: Severe cystocele, rectocele, or uterine prolapse altering normal bladder neck support.

Secondary Causes of Urinary Incontinence
​

• Neurological Pathologies: Stroke, Parkinson's disease, multiple sclerosis, spinal cord injuries, and diabetic neuropathy disrupting normal neural control of micturition.

• Systemic & Metabolic Conditions: Uncontrolled diabetes mellitus (osmotic diuresis), chronic constipation (rectal distension compressing the bladder), urinary tract infections (UTIs), and chronic cough (increasing intra-abdominal pressure).

• Genitourinary Syndrome of Menopause (GSM): Estrogen deficiency causing atrophy of the urethral and vaginal tissues, leading to reduced closure pressure and mucosal thinning.

• Medication-Induced Incontinence: Adverse effects from diuretics (polyuria/urgency), alpha-blockers (stress incontinence in women due to urethral relaxation), sedatives/hypnotics (functional or overflow due to immobility/sedation), anticholinergics (overflow from urinary retention), or calcium channel blockers.

• Functional & Environmental Barriers: Cognitive decline, severe arthritis limiting mobility, or inaccessible bathroom facilities.

Diagnostics
 

• Clinical History & Physical Examination: Detailed voiding diary (fluid intake, leakage episodes, frequency), assessment of symptom triggers, pelvic exam (evaluating for prolapse, atrophy, or stress leakage via cough test), and digital rectal exam (evaluating prostate size and rectal tone).

• Laboratory Testing:

• Urinalysis and urine culture to rule out infection, hematuria, or glycosuria.

• Renal function panel (BUN and creatinine) if urinary retention or upper tract compromise is suspected.

• Post-Void Residual (PVR) Measurement: Assessment via bladder ultrasound or catheterization to evaluate for urinary retention and overflow incontinence.

• Specialized & Urodynamic Testing: Complex urodynamic studies (cystometry, uroflowmetry, pressure-flow studies), cystoscopy, or multichannel video-urodynamics when diagnosis is uncertain or surgical intervention is planned.

Management 
 

Non-Pharmacological Management

• Behavioral & Lifestyle Modifications: Timed voiding schedules, bladder training, fluid management (reducing evening intake and avoiding bladder irritants like caffeine, alcohol, and artificial sweeteners), and weight loss for obese patients.

• Pelvic Floor Physical Therapy: Pelvic floor muscle training (Kegel exercises), biofeedback, and electrical stimulation supervised by specialized physical therapists.

• Physical Devices: Pessaries (support devices for pelvic organ prolapse and stress incontinence) and urethral inserts.

• Surgical Options: Mid-urethral slings (e.g., TVT/TOT) for stress incontinence, bladder neck suspensions, sacral neuromodulation, or surgical relief of bladder outlet obstruction (e.g., TURP for BPH).

Pharmacological Management

• Pharmacotherapy for Overactive Bladder (UUI):

  • Antimuscarinics/Anticholinergics (e.g., oxybutynin, tolterodine, solifenacin) to relax the detrusor muscle.

  • Beta-3 adrenergic agonists (e.g., mirabegron, vibegron) to promote bladder relaxation during filling without anticholinergic side effects.

• Hormone Therapy: Topical vaginal estrogen therapy for genitourinary syndrome of menopause to restore urethral and vaginal tissue health.

• Pharmacotherapy for Outlet Obstruction: Alpha-blockers (e.g., tamsulosin) or 5-alpha-reductase inhibitors (e.g., finasteride) for BPH-related overflow incontinence.

• Medication Reconciliation: Reviewing and modifying or discontinuing causative prescription medications (e.g., adjusting diuretic timing).